// App-Quantinova.ai

e16088 : Cost-effectiveness of pazopanib as first-line treatment of metastatic renal cell carcinoma from National Health Service United Kingdom perspective.

Researchers

Presenter

  • Barbara Elizabeth Ratto

Principal Investigators

  • Ankur Khare

  • Kapil Gudala

  • Praveen Gunda

Medical Centers

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

Locations

  • United States

  • India

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Pazopanib

  • Sunitinib

  • Tivopath

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved